Jewellers To Shun Turkish Tag, Rename Ornaments As Sindoor
Nagpur: The tag 'Turkish', given to large-sized ornaments like earrings and necklaces by jewellers due to the design's origin in Turkiye, will be dropped in India. Instead, jewellers plan to brand such designs as 'Sindoor', said chairman of Gems and Jewellery (Domestic) Council (GJC), Rajesh Rokde.
The GJC is a nationwide jewellers guild.
The word 'Sindoor' has been chosen in recognition of successful Operation Sindoor against terror infrastructure in Pakistan and Pakistan-occupied Kashmir following the dastardly Pahalgam terror attack.
This decision comes along with the GJC's call to jewellers to halt trade with Turkey due to its support for Pakistan. The name 'Turkish' was used for a wide range of premium jewellery, as such designs originally came from Turkiye.
However, imports have decreased substantially over the years as Indian jewellers have gained the expertise to make such ornaments. Despite this, the jewellery was marketed under the brand name 'Turkish', for its premium value.
Now, even the name will not be used, said Rokde.
The GJC has also made a call to stop all kinds of trade with Azerbaijan, which also has leanings towards Pakistan. "By halting trade, we send a clear message of unity and resolve," says a GJC note quoting Rokde.
Even though jewellery imports stopped, jewellers used to procure machinery from Turkiye. Appeals have been made to boycott Turkish equipment too, said another GJC member.
Nagpur: The tag 'Turkish', given to large-sized ornaments like earrings and necklaces by jewellers due to the design's origin in Turkiye, will be dropped in India. Instead, jewellers plan to brand such designs as 'Sindoor', said chairman of Gems and Jewellery (Domestic) Council (GJC), Rajesh Rokde.
The GJC is a nationwide jewellers guild.
The word 'Sindoor' has been chosen in recognition of successful Operation Sindoor against terror infrastructure in Pakistan and Pakistan-occupied Kashmir following the dastardly Pahalgam terror attack.
This decision comes along with the GJC's call to jewellers to halt trade with Turkey due to its support for Pakistan. The name 'Turkish' was used for a wide range of premium jewellery, as such designs originally came from Turkiye.
However, imports have decreased substantially over the years as Indian jewellers have gained the expertise to make such ornaments. Despite this, the jewellery was marketed under the brand name 'Turkish', for its premium value.
Now, even the name will not be used, said Rokde.
The GJC has also made a call to stop all kinds of trade with Azerbaijan, which also has leanings towards Pakistan. "By halting trade, we send a clear message of unity and resolve," says a GJC note quoting Rokde.
Even though jewellery imports stopped, jewellers used to procure machinery from Turkiye. Appeals have been made to boycott Turkish equipment too, said another GJC member.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
41 minutes ago
- Business Standard
Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation
In one of the largest pharma deals in the domestic market in recent years, Ahmedabad-based Torrent Pharmaceuticals will acquire a controlling stake in investment firm KKR-backed JB Chemicals and Pharmaceuticals (known as JB Pharma) at an equity valuation of ₹25,689 crore, which will be followed by the merger of the two entities. The deal will be executed in two phases — acquisition of the 46.39 per cent stake held by KKR in JB Pharma at ₹1,600 per share, amounting to ₹11,917 crore, followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at ₹1,639.18 per share. 'In addition to the above, Torrent has also expressed its intent to acquire up to 2.8 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR,' the company said in a statement on Sunday. The next step in the deal will be a merger between Torrent Pharma and JB Pharma through a scheme of arrangement, under which every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharma. The boards of directors of both companies have approved this arrangement. KKR had acquired 54 per cent of JB Pharma in July 2020 from the promoters and founders, the Mody family, for approximately ₹3,100 crore (or ₹745 per share). It sold a part of its stake in March this year through block deals for ₹1,459.8 crore. KKR has earned more than five times on its investment, with around 36 per cent gross IRR. For instance, Torrent Pharma has previously indicated plans to increase its medical representative (MR) strength by 23 per cent by the end of FY26, and the acquisition can aid in manpower augmentation. Torrent Pharma holds a 3.74 per cent share in the domestic market (according to Pharmarack, May 2025), while JB Pharma commands a 1.12 per cent share. Further, consolidation in key international markets is expected to offer greater scalability. Samir Mehta, executive chairman of Torrent Pharma, said they want to build on JB Pharma's heritage and platform for the future. 'Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint, offer immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market and builds a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Torrent has previously taken the inorganic route to grow its business and enter newer segments — in 2013, it acquired Elder Pharma's India-branded business; followed by the dermaceutical business of Zyg Pharma in 2015 and the API plant of Glochem Industries in 2016. Among other major deals, it bought the India-branded business of Unichem in 2017. Its last major acquisition was of skin-care products from Curatio Healthcare in 2022. Torrent Pharma is a highly domestic-focused company, drawing around 55 per cent of its consolidated revenues from the domestic formulations business. India sales grew by 13 per cent in FY25 to ₹6,393 crore. While the company has been outperforming industry growth in the domestic market, it is also planning to increase MR strength by 23 per cent by FY26-end. Torrent has a strong presence in the cardiovascular, gastrointestinal and neurology segments. JB too has prominent cardiac and gastro brands like Cilacar, Metrogyl and Rantac. Torrent is also working on launching GLP-1 products as a day-one launch in FY26. Analysts expect a 15 per cent sales CAGR in domestic formulations for Torrent Pharma over FY25–27. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific private equity at KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies.' Nikhil Chopra, chief executive officer and whole-time director of JB Pharma, pointed out that over the past five years, the company has emerged as one of India's fastest-growing pharmaceutical players. 'We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets,' Chopra said. JB Pharma posted 12 per cent revenue growth in FY25 to ₹3,918 crore, while its EBITDA rose 16 per cent to ₹1,087 crore, and PAT increased 19 per cent to ₹660 crore. Notably, KKR Private equity has invested $2 billion in India in 2024 and recently invested $600 million in Manipal Group via its private credit arm.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Contribute to stable borders, Xi tells Tibetans near Arunachal Pradesh
Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River, which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing $137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
an hour ago
- Time of India
Pharma mergers: Torrent to acquire majority stake in JB Chemicals for Rs 19,500 crore, open offer to follow
Torrent Pharmaceuticals on Sunday announced that it will acquire a controlling stake in JB Chemicals & Pharmaceuticals in a Rs 19,500 crore deal, making it India's second most-valued pharma firm by market capitalisation. Torrent will acquire 46.39% stake from the promoters for around Rs 11,917 crore, and an additional 2.80% from certain JB Chemicals employees for Rs 719 crore. Both transactions are being executed at Rs 1,600 per share, according to PTI report. Following this, Torrent will make an open offer for a 26% stake from public shareholders at Rs 1,639.18 per share, totalling Rs 6,842.8 crore, in line with listing regulations. 'This will be the second-largest transaction in the Indian pharma sector,' Torrent Pharma said in a statement, PTI quoted. Torrent Pharmaceuticals and global investment firm KKR jointly announced the deal, which values JB Chemicals at an equity valuation of Rs 25,689 crore on a fully diluted basis. The agreement includes a plan to merge the two entities, the company said. Torrent stated that the acquisition marks a strategic milestone, enabling it to build a future-ready healthcare platform that combines its chronic segment strength with JB Chemicals' presence in international CDMO (contract development and manufacturing organisation) operations Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
